Greywolf Therapeutics Appoints New CFO with Experience at Pieris Pharmaceuticals

Greywolf Therapeutics Bolsters Leadership with New CFO Appointment

Greywolf Therapeutics, a clinical-stage biotech firm based in Oxford, has announced the appointment of Darlene Deptula-Hicks as its new Chief Financial Officer. With over three decades of experience in corporate finance and capital markets, Deptula-Hicks brings a wealth of expertise that is expected to strengthen Greywolf's financial framework and operational capabilities. Previously, she served as CFO of F-star Therapeutics, where she successfully led the company through its NASDAQ public offering in 2020 and its subsequent acquisition in 2023. This background makes her an invaluable asset as Greywolf advances its innovative antigen modulation technology, which aims to redefine treatment strategies for autoimmune disorders, cancer, and infectious diseases.

Peter Joyce, CEO and Co-founder of Greywolf, expresses enthusiasm for Deptula-Hicks's appointment, highlighting her extensive experience in biotech financing as essential for the company’s future endeavors. Greywolf's cutting-edge technology focuses on antigen modulation to guide T cells within the immune system, a pivotal aspect of modern immunotherapy. The company’s lead modulator, GWRD5769, has shown promising results in a Phase I/II oncology trial, demonstrating its potential to effectively engage targets and mechanisms. Meanwhile, the second modulator, GRWD0715, is currently in preclinical development and focuses on autoimmune conditions, underscoring Greywolf's commitment to addressing significant unmet medical needs.

Deptula-Hicks’s deep involvement in the biotech sector extends beyond her role at F-star. She has held CFO positions at various companies, including Normunity and Pieris Pharmaceuticals, and currently serves on the boards of Abcuro and Avacta Therapeutics. Her multifaceted experience positions her well to navigate the complexities of biotech financial management and investor relations. At this pivotal moment for Greywolf, she expresses excitement about the company’s potential to meet the increasing demand for effective therapies, reinforcing the belief that strategic financial leadership will play a crucial role in the successful progression of their clinical trials.

In addition to her appointment, Greywolf’s innovative approach to antigen modulation signals a transformative direction in the biotech industry. The company's focus on harnessing the immune system's capabilities positions it uniquely within a competitive landscape. As the demand for novel therapies continues to grow, Greywolf's advancements could contribute significantly to improving patient outcomes across various therapeutic areas.

With Deptula-Hicks at the helm of financial operations, Greywolf aims to enhance its operational success and accelerate the development of its promising technologies, paving the way for future growth and significant contributions to the field of immunotherapy.